WALTHAM, Mass., March 06, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics
to address the medical needs of patients with kidney and vascular diseases, today announced that Company management will present at
the following upcoming investor conferences:
- Cowen and Company 38th Annual Health Care Conference in Boston, MA on Monday, March 12, 2018 at 12:00 pm ET;
and
- Oppenheimer 28th Annual Healthcare Conference in New York, NY on Wednesday, March 21, 2018 at 3:55 pm
ET.
About Proteon Therapeutics
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through
the development of novel, first-in-class therapeutics. Proteon's lead product candidate, vonapanitase, is an investigational drug
intended to improve hemodialysis vascular access outcomes. Proteon has completed enrollment in PATENCY-2, a Phase 3 clinical trial
evaluating vonapanitase in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous
fistula for hemodialysis. Proteon is also evaluating vonapanitase in a Phase 1 clinical trial in patients with peripheral artery
disease (PAD). For more information, please visit www.proteontx.com.
Investor Contact
George Eldridge, Proteon Therapeutics, Senior Vice President and Chief Financial Officer
781-890-0102
geldridge@proteontherapeutics.com
Media Contact
Ann Stanesa, Ten Bridge Communications
617-230-0347
proteon@tenbridgecommunications.com
